Genetic Technologies Ltd (GENE)

1.21
0.02 1.68
NASDAQ : Services
Prev Close 1.19
Open 1.20
Day Low/High 1.19 / 1.28
52 Wk Low/High 1.62 / 4.27
Volume 395.50K
Avg Volume 609.10K
Exchange NASDAQ
Shares Outstanding 11.44M
Market Cap 13.61M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.

Stalking an Entry in RetailMeNot

Can we wait for it to tell us whether to buy or avoid it.?

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

Findings presented at the 2014 San Antonio Breast Cancer Symposium

Why Genetic Technologies (GENE) Stock Is Spiking Today

Why Genetic Technologies (GENE) Stock Is Spiking Today

Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Breast Cancer Awareness Month: One Woman's Story Underscores Importance Of Understanding Risk

Breast Cancer Awareness Month: One Woman's Story Underscores Importance Of Understanding Risk

Maker of BREVAGenâ¿¢ breast cancer predictive risk test makes donation to Komen for the Cure in honor of Cyndi Pierre's courage to learn more and share her experience

Interesting GENE Call For February 2014

Interesting GENE Call For February 2014

Investors in Genetic Technologies Ltd. saw new options become available today, for the February 2014 expiration.

STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE

STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE

Phenogen Sciences, Inc. Presented Study Results at the 23rd Annual National Interdisciplinary Breast Center Conference

The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment

The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment

Local Physician One of the First in Nation to Use New Breast Cancer Predictive Risk Test

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Biotech Stocks Under $10 Soaring Higher

4 Biotech Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire)

BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire)

Dr. Owen Winsett of the Breast Center of Austin is one of the first physicians in the nation to make the BREVAGen™ predictive risk test available to his patients.

8 Stocks Under $10 Ripping Higher

8 Stocks Under $10 Ripping Higher

When a stock makes a large percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Break-Through Invention For Treating Cancer

ImmunAid Pty. Ltd.

Genetic Technologies Limited Announces Quarterly Activities Report For The Quarter Ended 30 September 2011

Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) today reported their quarterly activities report for the quarter ended 30 September, 2011.

Genetic Technologies’ BREVAGen™ Changing The Way US Physicians Assess Breast Cancer Risk

Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) today reported early insights from the US regional launch of BREVAGen™, its new, easy-to-use, predictive risk test for the tens of millions of women at ...

Genetic Technologies Limited Appoints Dr. Mervyn Cass As Company Director

The Board of Directors of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has with great pleasure appointed Dr.

Optimer Soars on Antibiotic Data

Optimer Pharmaceuticals proves that even in a bear market, small biotech stocks are still capable of doubling in price overnight.

Ties May Bind Apple's CEO to Board

Analysts ponder the state of independence of a board handpicked by Steve Jobs.

Wednesday's Small-Cap Winners & Losers

Systemax jumps, but Travelzoo declines.